JLPC(SH:600513)2024-03-05 16:00Financial Performance - The company's operating revenue for 2023 was CNY 2,174,100,305.52, representing an increase of 11.20% compared to CNY 1,955,156,781.66 in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 135,008,519.87, a decrease of 4.50% from CNY 141,370,528.08 in 2022[21]. - The net cash flow from operating activities increased by 25.95% to CNY 160,701,795.49 in 2023, up from CNY 127,590,488.44 in 2022[21]. - The total assets of the company at the end of 2023 were CNY 2,855,702,313.77, reflecting a growth of 5.18% from CNY 2,714,939,149.33 in 2022[21]. - The net assets attributable to shareholders increased by 6.91% to CNY 1,354,189,077.50 at the end of 2023, compared to CNY 1,266,623,651.58 at the end of 2022[21]. - Basic earnings per share for 2023 were CNY 0.47, down 4.08% from CNY 0.49 in 2022[22]. - The weighted average return on equity decreased by 1.26 percentage points to 10.38% in 2023, compared to 11.64% in 2022[22]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1.50 per 10 shares, totaling CNY 42,818,440.50, subject to shareholder approval[5]. - The total cash dividend amount for the year was 42,818,440.50 RMB, maintaining a consistent dividend distribution strategy[165]. - The cash dividend represents 31.72% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which amounted to 135,008,519.87 RMB[165]. Research and Development - Research and development expenses rose to CNY 132 million, marking a 42.95% increase compared to the previous year[51]. - The total R&D investment for the reporting period was CNY 141,355,992.93, accounting for 6.50% of the company's operating revenue[64]. - The number of R&D personnel is 305, representing 23.53% of the total workforce[62]. - The company has obtained a total of 131 domestic patents, including 28 invention patents and 87 utility model patents[46]. - The company has initiated III phase clinical trials for one Class I new drug and completed pre-IND submissions for another Class I new drug[88]. - The company has multiple projects under development, including a Class I innovative drug for type 2 diabetes currently in III phase clinical research[89]. Product Development and Innovation - The company successfully launched multiple new products, including 8 raw materials and formulations, and completed several registration applications[29]. - The company obtained nearly 40 patent authorizations in 2023, reflecting its commitment to innovation[29]. - The company is focusing on expanding its product portfolio, with 19 products receiving approval notifications or registration certificates during the reporting period[94]. - The company is actively pursuing new product development, including the completion of clinical research for various antihypertensive and anti-allergic medications[94]. Market and Sales Performance - Sales of the key product, Aipulete tablets, exceeded 200 million RMB, setting a historical sales record[30]. - The sales volume of the main product, Aipulete Tablets, was 9,123.59 million pieces, representing a year-on-year increase of 37.66%[55]. - The revenue from domestic sales was CNY 2.12 billion, with a gross margin of 49.03%, down 5.05 percentage points year-on-year[54]. - The company’s product sales network covers the entire country, optimizing sales policies based on regional characteristics[38]. Operational Efficiency and Management - The company has implemented a centralized procurement system to enhance internal control over procurement processes[39]. - The company has established a comprehensive quality management system to ensure drug quality throughout its lifecycle, which is critical for its development[123]. - The company has established a robust internal control management system in compliance with relevant laws and regulations, enhancing decision-making and management efficiency[168]. Governance and Compliance - The company is committed to maintaining a strong governance structure, ensuring compliance with laws and regulations, and protecting the rights of all shareholders[127]. - The board of directors has established specialized committees to oversee strategic, nomination, audit, and compensation matters, ensuring effective governance[128]. - The company emphasizes transparent information disclosure, ensuring all shareholders have equal access to information[129]. Environmental Responsibility - The company has committed to green development, aiming to build a safe, clean, and low-carbon enterprise[193]. - The company has implemented a comprehensive environmental risk assessment and training program, conducting three legal training sessions in 2023[186]. - The company has engaged a third-party operation and maintenance unit for environmental monitoring, ensuring effective management of wastewater and emissions[188]. Strategic Outlook - The company plans to enhance its core competitiveness through drug innovation, internationalization, and smart drug development in response to industry challenges[110]. - The company anticipates steady growth in the pharmaceutical manufacturing and distribution sectors driven by factors such as population aging and rising income levels[112]. - The company plans to significantly increase R&D investment in innovative drugs, specialty formulations, and high-end generics, aiming for breakthroughs in research levels[117].